ba0001pp162 | Cancer and bone: basic, translational and clinical | ECTS2013
Hadji Peyman
, Ziller May
, Maurer Tobias
, Autenrieth Michael
, Muth Mathias
, Ruebel Amelie
, May Christoph
, Birkholz Katrin
, Diebel Erhardt
, Gleissneer Jochen
, Rothe Peter
, Gschwend Juergen E
Introduction: The prospective, single-arm, open-label ZOTECT study was designed to assess the effect of zoledronic acid (ZOL) on bone-marker levels and potential correlations with disease outcomes in bisphosphonate-naive patients with bone metastases.Methods: Patients with bone metastases from prostate cancer (PC; n=301) or breast cancer (BC; n=99) who have not received bisphosphonates for ≥6 months were enrolled at 98 sites in Ge...